ORBIMED ADVISORS LLC 13D and 13G filings for X4 Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 7:36 pm Purchase | 2023-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | ORBIMED ADVISORS LLC | 383,148 6.700% | 38,860 (+11.29%) | Filing |
| 2023-02-14 5:24 pm Purchase | 2022-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | ORBIMED ADVISORS LLC | 344,288 8.200% | 283,077 (+462.46%) | Filing |
| 2022-02-11 5:08 pm Purchase | 2021-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | ORBIMED ADVISORS LLC | 61,212 6.400% | 12 (+0.02%) | Filing |
| 2021-03-25 4:15 pm Purchase | 2021-03-23 | 13G | X4 Pharmaceuticals, Inc. XFOR | ORBIMED ADVISORS LLC | 61,200 7.600% | 19,567 (+47.00%) | Filing |